US Patent

US10799487 — Compositions for the treatment of hypertension

Method of Use · Assigned to George Institute for Global Health · Expires 2038-01-23 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical compositions for treating hypertension that combine an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

USPTO Abstract

Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker.

Drugs covered by this patent

Caduet (Amlodipine Besylate) · Pfizer Inc.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3448`	—	Caduet

Patent Metadata

Patent number: US10799487
Jurisdiction: US
Classification: Method of Use
Expires: 2038-01-23
Drug substance claim: No
Drug product claim: Yes
Assignee: George Institute for Global Health
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.